Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cryo Cell International (CCEL) Operating Leases (2020 - 2026)

Cryo Cell International's Operating Leases history spans 7 years, with the latest figure at $368941.0 for Q1 2026.

  • Quarterly results put Operating Leases at $368941.0 for Q1 2026, down 4.62% from a year ago — trailing twelve months through Feb 2026 was $368941.0 (down 4.62% YoY), and the annual figure for FY2025 was $474628.0, down 6.02%.
  • Operating Leases for Q1 2026 was $368941.0 at Cryo Cell International, down from $474628.0 in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $967116.0 in Q2 2023 to a low of $242039.0 in Q1 2023.
  • The 5-year median for Operating Leases is $505053.0 (2024), against an average of $546557.8.
  • The sharpest move saw Operating Leases soared 217.7% in 2024, then plummeted 60.56% in 2025.
  • Year by year, Operating Leases stood at $313298.0 in 2022, then surged by 171.93% to $851938.0 in 2023, then crashed by 40.72% to $505053.0 in 2024, then dropped by 6.02% to $474628.0 in 2025, then fell by 22.27% to $368941.0 in 2026.
  • According to Business Quant data, Operating Leases over the past three periods came in at $368941.0, $474628.0, and $577202.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.